Pierre Rivière, Ph.D.

 

Pierre Rivière is a Co-founder & the Chief Executive Officer (CEO) of Nuvie Bio.

 

Pierre has over 30 years of industry experience in leadership roles in discovery and early-stage development in startups, medium and large pharma, during which he developed advanced expertise in peptide therapeutics and biologics.

 

Most recently, he founded and served as CEO of Peptide Logic, an NIH-funded, discovery-stage biotech company developing peptide-antibody conjugates and monoclonal antibodies for neuroscience indications.

 

Previously, Pierre was Chief Scientific Officer at CovX, a then wholly owned biotech unit of Pfizer, deploying a proprietary peptide-antibody conjugate technology for oncology indications. He was also a Senior Vice President of Pfizer Worldwide Research and Development, and a member of Pfizer's leadership team.

 

Prior to his tenure at Pfizer, Pierre was President of the Ferring Research Institute in San Diego, and Senior Vice President of Research at Ferring Pharmaceuticals.

 

Earlier in his career, Pierre co-founded the Peptide Therapeutics Foundation and the Annual Peptide Therapeutics Symposium.

 

He earned his Ph.D. in Animal Biology and Physiology from the Institut National Polytechnique de Toulouse and completed post-doctoral research in pharmacology at the University of Arizona.